Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?
- 30 November 2017
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 117 (11), 2013-2025
- https://doi.org/10.1160/th17-03-0219
Abstract
Thrombin triggers activation of platelets through protease-activated receptor 1 (PAR-1) and PAR-4. Both receptors are widely expressed and exert multiple platelet-independent functions. PAR signalling contributes to healing responses after injury, by promoting cytokine activity and cellular growth and mobility. Uncontrolled PAR activation, however, can prevent timely resolution of inflammation, enhance thrombogenic endothelial function and drive adverse remodelling. The specific role of PAR-4 in thromboinflammatory vascular disease has been largely underestimated, given the relatively limited expression of PAR-4 in non-platelet cells under healthy conditions. However, unlike PAR-1, PAR-4 expression adapts dynamically to numerous stimuli associated with thromboinflammation, including thrombin, angiotensin II, sphingosine-1-phosphate (S1P), high glucose and redox stress, suggesting expression is switched on ‘at need’. Prostacyclin negatively regulates PAR-4 expression at the post-transcriptional level, which may serve to fine-tune thrombin responses and limit these to the injury site. PAR-4 elicits inflammatory, mitogenic and proliferative actions not only in response to thrombin but also to numerous other inflammatory proteases, and can cross-talk with other receptor systems such as S1P and adenosine receptors. Accordingly, PAR-4 has emerged as a candidate player in vessel disease and cardiac post-infarction remodelling. Currently, PAR-4 is a particularly promising target for safer anti-thrombotic therapies. Recent studies with the PAR-4 antagonist BMS-986120 lend support to the concept that selective antagonism of PAR-4 may offer both an effective and safe anti-thrombotic therapy in the acute thrombotic setting as well as an anti-inflammatory strategy to prevent long-term progressive atherosclerotic disease in high-risk cardiovascular patients.This publication has 100 references indexed in Scilit:
- P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cellsPurinergic Signalling, 2012
- Protease‐activated receptors and myocardial infarctionIUBMB Life, 2011
- Arrestin-2 Differentially Regulates PAR4 and ADP Receptor Signaling in PlateletsPublished by Elsevier BV ,2011
- Potential Antifungal Effects of Human Platelets against Zygomycetes In VitroThe Journal of Infectious Diseases, 2009
- Is thrombin a key player in the 'coagulation-atherogenesis' maze?Cardiovascular Research, 2009
- Human Platelets AttenuateAspergillusSpecies via Granule‐Dependent MechanismsThe Journal of Infectious Diseases, 2008
- Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein CThe Journal of Experimental Medicine, 2007
- Blockade of protease-activated receptors on T cells correlates with altered proteolysis of CD27 by gingipains ofPorphyromonas gingivalisClinical and Experimental Immunology, 2007
- Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerizationProceedings of the National Academy of Sciences of the United States of America, 2007
- PAR4, but Not PAR1, Signals Human Platelet Aggregation via Ca2+ Mobilization and Synergistic P2Y12 Receptor ActivationPublished by Elsevier BV ,2006